HUNT VALLEY, Md., July 27, 2011 /PRNewswire/ — Pharmaceutics
International, Inc. (Pii), a leading contract development and
manufacturing organization, today announced that it has added
hot melt extrusion (HME) to its portfolio of formulation and
process development solutions. The company has purchased a 16mm and
an 18mm Leistritz twin screw extruders. This investment enables Pii
to carry out feasibility studies, using just a few grams of active
pharmaceutical ingredient, to pilot scale cGMP productions for
Phase I and II clinical trials using HME.
A well known processing technology, hot melt extrusion offers a
number of benefits to optimize drug formulation, including the
development of solid dispersions for bioavailability enhancement of
poorly soluble compounds and controlled release drug delivery.
“Pii’s investment in hot melt extrusion is part of the company’s
goal of providing our clients with a comprehensive package of
bioavailability enhancement capabilities,” said Steve King, senior
vice president of Pii. “This proven technology further enables us
to meet the challenges of poorly soluble compounds and advance our
client’s compounds through the development pipeline.”
In addition to the new hot melt extrusion capability, Pii’s
solutions for bioavailability enhancement include spray drying,
solvent-based fluid bed processing, soft gels and liquid filled
hard capsules.
About Pharmaceutics International, Inc.
Pharmaceutics International, Inc. (Pii) is a privately held Drug
Delivery Solutions company providing dosage form development and
GMP Manufacturing services to the global pharmaceutical industry.
Pii’s vision is to become the benchmark in pharmaceutical product
development outsourcing. Headquartered in Hunt Valley Maryland USA
with European facilities in the UK, Pii offers preformulation
testing, formulation development and clinical trial material and
commercial manufacture of parenteral, solid, semi-so
‘/>”/>
